Literature DB >> 34955382

The rare disease neurofibromatosis 1 as a source of hereditary economic inequality: Evidence from Finland.

Edvard Johansson1, Roope A Kallionpää2, Petri Böckerman3, Sirkku Peltonen4, Juha Peltonen5.   

Abstract

PURPOSE: This study investigated whether individuals with neurofibromatosis 1 (NF1) fare worse than individuals without NF1 in terms of economic well-being. NF1 is relatively common in the population and provides an informative case of a rare hereditary disease.
METHODS: We examined a subset of 692 individuals with verified NF1 from the Finnish total population-based NF1 cohort and compared that with 7407 control individuals matched for age, sex, and municipality during 1997-2014. Economic well-being was operationalized with annual work earnings and total income, including social income transfers.
RESULTS: NF1 significantly worsened economic well-being. Low education, increased morbidity, and reduced labor market participation partly explained the effect of NF1. Yet, NF1 was independently associated with lower income even after adjusting for these factors. Furthermore, NF1 had a larger negative effect on income from work than it had on total income, which indicated that the Finnish social security system partly compensated the labor market losses suffered by individuals with NF1. NF1 had a larger impact on economic inequality for men than for women.
CONCLUSION: NF1 contributes to economic inequality. A hereditary disease may convey worse economic well-being over several generations.
Copyright © 2021 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neurofibromatosis; Nordic model; Rare diseases; Social income transfers; Wages

Mesh:

Year:  2021        PMID: 34955382     DOI: 10.1016/j.gim.2021.11.024

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  1 in total

1.  Case report: Bilateral spinal neurofibromatosis.

Authors:  Ali Baradaran Bagheri; Sepehr Aghajanian; Aliasghar Taghi Doulabi; Mehdi Chavoshi-Nejad; Somayeh Sorouredin Abadi
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.